Can super-antibody drugs be tamed?
D000818:Animals; D000906:Antibodies / Q000009:adverse effects* / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity / Q000276:immunology; D002986:Clinical Trials as Topic / Q000009:adverse effects; D000882:Haplorhini / Q000276:immunology; D006801:Humans; D008131:London; D008297:Male; D051379:Mice; D018448:Models, Immunological; D013045:Species Specificity
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C456519:visilizumab; C509303:TGN-1412